Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma

Anish K Simhal, Kylee H Maclachlan, Rena Elkin, Jiening Zhu, Saad Usmani, Jonathan J Keats, Larry Norton, Joseph O. Deasy, Jung Hun Oh, Allen Tannenbaum

Blood (2022) 140 (Supplement 1): 9991–9992.

https://doi.org/10.1182/blood-2022-167248

Published: 2022

Journal Articles

The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway

Enze Liu, Nathan Becker, Parvathi Sudha, Chuanpeng Dong, Yunlong Liu, Jonathan J Keats, Gareth J. Morgan, Brian A. Walker

Blood (2022) 140 (Supplement 1): 4259–4260.

https://doi.org/10.1182/blood-2022-167322

Published: 2022

Journal Articles

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Blood (2022) 139 (16): 2471–2482.

https://doi.org/10.1182/blood.2021015161

Published: 2022

Includes: Supplemental data

Journal Articles

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Sheri Skerget, Daniel Penaherrera, Joseph Mikhael, Jonathan J Keats

Blood (2021) 138 (Supplement 1): 726.

https://doi.org/10.1182/blood-2021-148138

Published: 2021

Journal Articles

Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients

Tarek H. Mouhieddine, Chidimma Nzerem, Robert A. Redd, Andrew Dunford, Matthew Joseph Leventhal, Romanos Sklavenitis-Pistofidis, Sabrin Tahri, Habib El-Khoury, David P. Steensma, Benjamin L. Ebert, Robert J. Soiffer, Jonathan J Keats, Shaadi Mehr, Daniel Auclair, Adam S. Sperling, Chip Stewart, Gad Getz, Irene M. Ghobrial

Blood (2021) 138 (Supplement 1): 1091.

https://doi.org/10.1182/blood-2021-152025

Published: 2021

Journal Articles

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Ryosuke Shirasaki, David L. Jaye, Jonathan J. Keats, Benjamin Oberlton, Nisha S. Joseph, Craig C. Hofmeister, Leonard T. Heffner, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Constantine S. Mitsiades, Jonathan L. Kaufman, Lawrence H. Boise

Blood (2021) 137 (26): 3604–3615.

https://doi.org/10.1182/blood.2020007899

Published: 2021

Includes: Supplemental data

Journal Articles

Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Benjamin G Barwick, PhD, Vikas A. Gupta, MD PhD, Shannon M Matulis, PhD, Jonathan C Patton, B.S., Doris R Powell, MA, Yanyan Gu, MD PhD, David L. Jaye, MD, Karen N Conneely, PhD, Yin C Lin, PhD, Craig C Hofmeister, MDMPH, Ajay Nooka, MDMPH, Jonathan J Keats, PhD, Sagar Lonial, MD FACP, Paula M Vertino, PhD, Larry H. Boise, PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140717

Published: 2020

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Blood (2019) 134 (Supplement_1): 4407.

https://doi.org/10.1182/blood-2019-130901

Published: 2019

Journal Articles

The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias

Linda B Baughn, PhD, Zhou Li, MS, Kathryn E. Pearce, Celine M. Vachon, PhD, Mei-Yin Polley, PhD, Jonathan J Keats, PhD, Eran Elhaik, PhD, Michael L. Baird, PhD, Terry Therneau, PhD, James R. Cerhan, MD PhD, P. Leif Bergsagel, MD, Angela Dispenzieri, MD, S.Vincent Rajkumar, MD, Yan Asmann, PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 4362.

https://doi.org/10.1182/blood-2019-124979

Published: 2019

Journal Articles

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Rafail Nikolaos Tasakis, MSc, BSc, Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Jonathan J Keats, PhD, Daniel Auclair, Deepu Madduri, MD, Joshua Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, F. Nina Papavasiliou, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3092.

https://doi.org/10.1182/blood-2019-130669

Published: 2019

Journal Articles

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Donald Jackson, PhD, Michael Robbins, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Samir Parekh, MD, Jonathan J Keats, PhD, Daniel Auclair

Blood (2019) 134 (Supplement_1): 3093.

https://doi.org/10.1182/blood-2019-131274

Published: 2019

Journal Articles

Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis

Austin Christofferson, BSc, Sheri Skerget, PhD, Jessica Aldrich, Christophe Legendre, PhD, Sara Nasser, PhD, Jennifer Yesil, Daniel Auclair, The MMRF CoMMpass Network, Sagar Lonial, Jonathan J Keats, PhD

Blood (2019) 134 (Supplement_1): 1805.

https://doi.org/10.1182/blood-2019-132152

Published: 2019

Journal Articles

Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study

Sheri Skerget, PhD, Austin Christofferson, BSc, Sara Nasser, PhD, Christophe Legendre, PhD, The MMRF CoMMpass Network, Jennifer Yesil, Daniel Auclair, Sagar Lonial, Jonathan J Keats, PhD

Blood (2019) 134 (Supplement_1): 1782.

https://doi.org/10.1182/blood-2019-130697

Published: 2019

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

Benjamin G Barwick, PhD, Sheri Skerget, PhD, Jonathan J Keats, PhD, Daniel Auclair, Sagar Lonial, Lawrence H. Boise, PhD, Paula M Vertino, PhD, Doris R Powell, MA

Blood (2019) 134 (Supplement_1): 858.

https://doi.org/10.1182/blood-2019-124422

Published: 2019

Journal Articles

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Hearn Jay Cho, MD, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Jessie Han, Deepak Perumal, PhD, Jonathan J Keats, PhD, Daniel Auclair, PhD, Ajai Chari, MD, Sundar Jagannath, MD, Samir Parekh, MD, Alessandro Lagana, PhD

Blood (2018) 132 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2018-99-118692

Published: 2018

Journal Articles

Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis

Daniel Penaherrera, BSc, Sheri Skerget, PhD, Austin Christofferson, BSc, Jessica Aldrich, Sara Nasser, PhD, Christophe Legendre, Martin Boateng, BS, Lori Cuyugan, Jonathan Adkins, Erica Tassone, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 1895.

https://doi.org/10.1182/blood-2018-99-119610

Published: 2018

Journal Articles

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Brandon Chen, Wong Pamela, B.S., Daniel Auclair, PhD, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Christine M Dunham, PhD, Sagar Lonial, MD, Joseph Opferman, PhD, Shannon M Matulis, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 951.

https://doi.org/10.1182/blood-2018-99-113444

Published: 2018

Journal Articles

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Shannon M Matulis, PhD, Vikas A. Gupta, MD PhD, Izabelle Brown, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Paola Neri, MD, Nizar Bahlis, MD, Jonathan L Kaufman, MD, Leonard Heffner, MD, Sagar Lonial, MD, Ajay K Nooka, MDMPH, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 952.

https://doi.org/10.1182/blood-2018-99-113504

Published: 2018

NARROW

Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma

The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

High-Risk Gene Expression Subtype Provides Molecular Basis for Different Clinical Presentation of Primary and Secondary Plasma Cell Leukemia

Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis

Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only